Biochimica et biophysica acta. Molecular basis of disease · 2026
Pretreatment of ADSCs with resveratrol-functionalized selenium nanoparticles alleviate CCl4-induced liver fibrosis in mice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Shuangjuan, Zhang Ziqiang, Luo Dongliu, Wen Fengyun, Zhu Xuemin, Chen Xiaoguang, Zhang Tianao, Feng Jingwen, Hou Leyao, Liu Yumei
Аннотация
BACKGROUND: Liver fibrosis (LF) is an abnormal repair reaction after chronic liver injury. Currently, adipose-derived mesenchymal stem cells (ADSCs) are widely used in the treatment of liver diseases. However, the therapeutic effect of ADSCs is affected by the damaged microenvironment. In this study, a resveratrol-functionalized nano‑selenium (Res@SeNPs) formulation was prepared to investigate whether Res@SeNPs pretreatment can enhance the therapeutic effect and alter the potential mechanism of ADSCs in carbon tetrachloride (CCl4) -induced LF in mice.
METHODS: Res@SeNPs were prepared and ADSCs pretreated with Res@SeNPs were cocultured with CCl4-injured BRL-3A cells in vitro. In vivo, ADSCs pretreated with Res@SeNPs were injected into the tail vein of a CCl4-induced LF mouse model.
RESULTS: Res@SeNPs were successfully prepared. In vitro, after coculture with BRL-3A cells, the function of damaged BRL-3A cells was improved. In vivo, Res@SeNPs-pretreated ADSCs effectively alleviated liver function damage and fibrosis in mice with LF. This may be related to the inhibition of oxidative stress, the reduction in apoptosis and the inhibition of the activation of the apoptosis signal-regulated kinase 1/c-Jun N-terminal kinase/p38 mitogen-activated protein kinase (ASK1/JNK/p38) pathway.
CONCLUSION: Our study suggested that Res@SeNPs pretreatment can enhance the therapeutic effect of ADSCs on LF in mice, and in vivo findings indicated the potential mechanism of ADSCs, providing new ideas for the treatment of LF.
METHODS: Res@SeNPs were prepared and ADSCs pretreated with Res@SeNPs were cocultured with CCl4-injured BRL-3A cells in vitro. In vivo, ADSCs pretreated with Res@SeNPs were injected into the tail vein of a CCl4-induced LF mouse model.
RESULTS: Res@SeNPs were successfully prepared. In vitro, after coculture with BRL-3A cells, the function of damaged BRL-3A cells was improved. In vivo, Res@SeNPs-pretreated ADSCs effectively alleviated liver function damage and fibrosis in mice with LF. This may be related to the inhibition of oxidative stress, the reduction in apoptosis and the inhibition of the activation of the apoptosis signal-regulated kinase 1/c-Jun N-terminal kinase/p38 mitogen-activated protein kinase (ASK1/JNK/p38) pathway.
CONCLUSION: Our study suggested that Res@SeNPs pretreatment can enhance the therapeutic effect of ADSCs on LF in mice, and in vivo findings indicated the potential mechanism of ADSCs, providing new ideas for the treatment of LF.